Type 1 Diabetes Vaccine: Does Diamyd Have a Winning Formula?
XTalks
SEPTEMBER 15, 2020
A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. In the trial, the vaccine was injected directly into the lymph nodes of type 1 diabetic individuals. The DIAGNODE-2 Trial.
103 
Let's personalize your content